Aptinyx Inc.

Company Review

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. The company has a collaboration agreement with Allergan plc. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.

  • Biotechnology
  • Evanston, Illinois
Primary Stock Exchange Listings

Ticker Symbol:

APTX

Nasdaq
United States

Stock Price

Latest Closing Price
4.99USD
Thu, 2 Jul 2020

Performance

Registration required

Please login or create a free account to view all available contents of this section.

Create Account

Valuation

Registration required

Please login or create a free account to view all available contents of this section.

Create Account

Health Check

Registration required

Please login or create a free account to view all available contents of this section.

Create Account

Financial Reports

Registration required

Please login or create a free account to view all available contents of this section.

Create Account

Similar Companies

↑ back to top